Govt’s
patronage of Nigerian coys ’ll boost profit – Okafor, MD, May & Baker
 |
| Okafor |
“When you start
manufacturing in Nigeria, you are already 40 per cent disadvantaged”. According
to Mr. Nnamdi Okafor, the Managing Director of May & Baker (M&B)
Nigeria Plc, apart from contending with bad roads to move your goods and
epileptic power supply, which makes his company to shell out an average of
N20million every month to power its plants, you still have to wrestle with the
global brands that swoop down on Nigeria for contracts. And, not bound by any
government policies, these foreign companies are desperate to elbow out whoever
stands on their way.
“That is why we are
asking the government to give us some level of preference. We cannot develop
capacity when we are not protected. The Indians, the Chinese, at some point in
their development had to protect their local manufacturers so that they can
build capacity”, he said.
In a media parley in
Lagos recently, the M&B boss bared his mind on why Nigerian manufacturers
want domestic preference jacked up from its current level of 15 per cent; the
efforts being made by his company to help contain the spread of Ebola and other
sundry issues.
Excerpts:
Global competitiveness
This is a situation I believe
that we all should be conversant with because if you start the process of
manufacturing, some of those things, the expenses you are incuring, the
environment where you manufacture are the factors that will affect your cost
structure.
So when you manufacture in
Nigeria, you are already 40 per cent disadvantaged because- unlike when
somebody is manufacturing in Asia or in
Europe where you don’t have to bother about power, you don’t have to
bother about water, about road to move your goods and all of that- here you
come up with all sorts of cost. Of course, they have economy of scale which has
to do with large scale manufacturing, they are the ones that are getting all
the major stakeholders from donor agencies. S o they have built up the economy
of scale which also break down the cost per unit for their products. Of course,
you are also aware that about 80-99 per cent of inputs into pharmaceuticals
from overseas are coming into Nigeria. So where you have to manufacture with
ingredients or outputs from Europe, and you have to compete with the same
company who is giving you their outputs, definitely it is going to be
difficult. What we are doing, in terms of quality, we are competitive. And that
is why we build the PharmaCentre.That is why we want the facility to be the
best you can get in any part of the world. So as far as quality is concerned, I
think we are there.
The other factor is also part of
cost. And that is why we talk about patronage because if you build capacity,
you must have market where you are going to sell your products. As we increase
the level of our capacity, the cost will start coming down. And then, we are
hoping that the good job that is being done by the current administration
especially as regards power is sustained, the cost of power will come down, We
spend on the average over N20million every month to provide power. We don’t use
the public grid to provide power to our plants. So these are the costs that we
can do without.
70 years of M&B
Today, May & Baker Nigeria
Plc is 70 years as a business in Nigeria. And we are celebrating the past and a
new beginning for the company. The company was founded on September 4, 1944 as
Nigeria’s first pharmaceutical company and began local manufacture of medicines
in 1976. In 2002, the company became 100 per cent owned by Nigerians
following the divestment of our foreign partners. The company began an
expansion and diversification programme in 2005 which gave rise to the creation
of new businesses and subsidiaries. In 2005, Biovaccines, a local vaccine production
subsidiary, was set up in partnership with the Federal Government. In 2006, we
constructed a multi-billion naira food processing factory, while in 2008, we
commenced construction of a World Health Organization Standard Pharmaceutical
production facility which was completed and commissioned on June 27, 2011.We
saw the need for global best practice and competitiveness. We therefore
commenced the process of international certification of our manufacturing plant
for Good Manufacturing Practice (GMP) of the World Health Organization(WHO) and
the United States Food and Drugs Administration (USFDA). We are in line
to obtaining the WHO GMP certification for this facility and pre-qualification
for our products and hopefully with these, the gate into global pharmaceutical
market will open for us.
Following these huge capital
investments on capacity acquisition and expansion, our company has, in the past
four years, been undergoing some restructuring and re-positioning to
effectively contain the expected short term negative impact of these
investments on the business, while waiting to begin to derive expected big
returns on the investments. Consequently, the management has begun the process
of consolidating all Pharma manufacturing operations by transferring substantial
product lines from Ikeja to the new pharmaceutical plant in Ota, the M&B
Pharmacentre, which has the capacity to produce 4.5 billion tablets and 37.5
million bottles of 60 ml liquid preparations annually. That way, we hope to
derive the advantage of economy of scale and minimize costs.
We are pleased that, in recent
years, the Federal Government through the Federal Ministry of Health and the
National Agency for Food and Drug Administration and Control (NAFDAC) has made
some efforts towards supporting local pharmaceutical manufacturers. However,
much more still need to be done in the areas of patronage, protection through
restriction of unbridled massive importation of basic essential medicines and
promoting private sector capacity building and technology development in
critical areas like vaccines production.
Anniversary
We are marking our 70th
anniversary for three main reasons:Seventy is a landmark age and deserves to be
celebrated. The second reason is that this company has, during these long years,
saved the lives of millions of Nigerians through its quality efficacious
medicines and the third is that this is the time May & Baker has come full
circle - growing from a foreign tutelage and ownership to a wholly
indigenous player and is now heading back to global focus. It is a significant
new beginning for us.
In commemoration of our 70th
anniversary we have decided to give back to society through some projects in
key areas of need. We are donating sickbays to public schools across the
country. The project kicked off with three pilot schools in Lagos State when we
donated sickbays to three public primary schools in the state. The beneficiary
schools are Central Primary School, Ikeja, United African Methodist Primary
School, Eleja, Oyingbo and St. Agnes Primary School, Sabo, Yaba.
Each sick bay is fully air
conditioned and equipped to the standard of a clinic with beds, medical
instruments, drugs, recovery motifs and television sets to enable the children
feel less of their pains while receiving attention. That way we hope to touch
the lives of some less privileged ones. Our intention is to make the charity
visitation an annual affair. So in September every year, we plan to mark the
birthday of the company by visiting charity homes across the country with gifts
that can alleviate their conditions.
Job creation
Well, we have a factory in Ikeja
here. We have two factories in Ota; we have locations in Aba, Kano.We also plan
to set up some beverage plants in Abuja, where we have acquired some expanse of
land, and then Onitsha, to add to job creation in other parts of Nigeria. But
the fact is that we want to ensure that we are getting results from the ones
(investments) that we have made. So, our first priority is to ensure that the
factories we have are working optimally before we start going to other
investments. As you are aware, we borrowed money from banks to make those
investments and we can’t go to the banks again to borrow money to make other
ones. That is why we want to ensure that the investments we have made, we are
leveraging very well on them before we go ahead to make further investment.
Ebola
As far as the Ebola disease is
concerned, our response as a country would have been much different and better
if Nigeria had technology for local production of vaccines. But we are working
on products that we hope should be in the market very soon that will help to
control the spread of Ebola virus. Of course, as you are aware, we have this
joint venture company with the Federal Government of Nigeria for vaccine
production. What that company was meant to do was to acquire technology for
local capacity production of vaccines to contain diseases like this viral Ebola
Viral Disease (EVD). You know, if we have technology, that will go a long way to help produce vaccine to ensure
that this dreadful disease does not show up in future again.

As for that joint venture
company, Biovaccine, you know, anything that has to do with the government
takes its course. So that company started operations and stopped for some reasons.
We are trying to resolve some issues which are very contentious. And I just
want to say to you that we have gone very far in resolving almost all the
issues. And hopefully, very soon, this company will come back to life.
Raising funds
We had planned to be in the
market some months ago. But, for some reasons, we tried to put it off because
we are also trying to ensure that we get all the major stakeholders and the
board to be ready. We have to make sure they are ready to take up their shares
otherwise we will not do better. That is what we are looking for. And as you
are aware, we have gotten the approval of our shareholders at the last AGM and
we are looking up to the board to give the go-ahead. We also have stand-by
investors that would be ready to put in money. But, as I said earlier, we want
to make sure that our Nigerian major shareholders take up their rights. That is
very important to us.
CSR
As far as Corporate Social
Responsibility (CSR) is concerned, we have started this project of donating
sick bays to schools. As you know, Ebola virus spread very fast, particularly
where we have children who can not imbibe the basic rules (to prevent it).We
also want to make sure that they have the capacity to handle the sick when they
arrive. So we are going to be donating these centres across Nigeria and we also
want to ensure that they have drugs and also equipment for checking Ebola. In
most of the centres, a mention was made about sustainability, that they have to
get light to operate the things that we donate to them. So we accepted to
provide generators for them. And we also gave commitment that we are going to
continue to refill their (stock and meet their) need for drugs. In fact, we are
not alone, for the fact that the local government chairmen (of these areas)
gave commitment to provide doctors and nurses to ensure that they sustain what
we have started.
As far as the host community is
concerned, we started from our base in Ikeja here.The first sick bays we
donated was in Ikeja. That is the one that is closest to us. In Ota, we donated
transformer and installed that transformer to ensure that the host community
has power. Before we got there, there was no light in that environment. We also
ensure that we attend the meetings of the community. And we made donations to
them to ensure that we sustain whatever plan they have, especially, regarding
security of the area.
Domestic preference
One, looking at it from the true
sense of local content policy, it is not very applicable to our industry. What
we are asking government to do is to give us what we call domestic preference
for those of us who are manufacturing locally because we know that we have to
get our materials from outside Nigeria. And it is going to be difficult for us
to compete with the same people who gave us their outputs. And because we know
that we cannot develop capacity if we are not protected because there is no
country in the world that just woke up
and built capacity. The Indians , the Chinese, at some point in their
development., they had to protect their local manufacturers so that they can
build capacity. We are asking the Federal Government to give us some level of
preference which was approved. And on paper, there is 15 per cent domestic
preference when you are bidding for contracts and when you want to compete with
pharmaceutical companies from overseas. So that is what we have and we are
happy We want that 15 per cent to be increased because we feel it was not
sufficient to cover cost at that stage for the fact that, at onset, you are 40
per cent disadvantaged and we found out that you don’t make profit really. Some
of the people you are struggling with for these contracts are ready to even
sell at discount, but they want to get you out. Yet, like Oliver Twist, we said
yes, the 15 per cent is good, but it should be increased because that is not
even good enough. And government must ensure that it applies to all the
corporate tenders because if the
law says that if it is not put it
in publication or advert in newspaper, you can not apply , then we are saying
it must apply to all the tenders. It is noted that when the foreign companies
bring their money ,they are not bound to the policies of government.
Counterfeiters
We are working to repackage our
products in better packs. We also collaborate with our customers to ensure that
they work with us and give us feedback. What is happening in our brands? Yes,
in the last couple of years, we have not got any incidence. We collaborate with
regulatory agencies to stamp out the fakers. The last incident we had was that
of a company that was trying to copy our designs because they felt that our
brands were doing well in the market. So they wanted to ride on the back of the
brands to push their products to the market. However, some of the fakers retraced
their steps when the regulatory agencies stepped in. But it still remains one
that we are talking to now.
 |
| Okafor |
Accessing foreign market
As a company, we realize that we
shouldn’t do what a 10-year old or 16-year old are doing. That, in the first
instance informed the decision to build the Pharmacentre. As of now in our
company, we have world class facility that no company has in Nigeria. The whole
idea is to develop some high-tech products. We are going to do that through
collaboration. We are talking with some foreign companies to see if they have
capacity to enable us acquire technology from these companies manufacturing
drugs which Nigeria depends on their importation today. Of course, you aware
that to develop technology is not an easy thing. We, on our own, are doing our
best and I am proud to say that the products that we want certified is our own
technology. We didn’t borrow the technology from anybody. And they are doing
very well. Of course, there are products that are in very sensitive areas, like
the vaccines. We need to get technology on those products. We believe that by
the time we develop these products, we should be able to move them outside
Nigeria because you cannot move paracetamol or basic generic products from this
country. But by the time we are able to have some specialized products that are
of global standards, we will be able to access those markets. That is exactly
what we want to do going forward.
And as far as the GMP
certification is concerned, I think we have advanced very well. The reason we
have not announced was that we have to be very careful. The first time the WHO
inspectors came, we had not started production. So they couldn’t inspect us.
And you have to go through certain inspections before they could pass you. So
we have gone through all those inspections and we are just waiting for them.
All I want to say is that we are very much advanced and we are hopeful that
soon, the results will be announced.